Pharmaceutical and Medical Device Expenditure Measures in the 2026 Budget Law and the Revision of Payback Mechanisms under the Consolidated Pharmaceutical Legislation //
Abolition of the 1.83% Payback and Reinstatement of the 5% Price Reduction under the 2026 Budget Law //
The future of accessible digital healthcare: insights from the new AgID Guidelines //
The UPC transitional regime, Venice Court’s 12 November 2025 judgment and its implications for the pharmaceutical sector